NASDAQ:CRVS - Nasdaq - US2210151005 - Common Stock - Currency: USD
NASDAQ:CRVS (5/22/2025, 3:08:02 PM)
3.565
-0.06 (-1.79%)
The current stock price of CRVS is 3.565 USD. In the past month the price increased by 3.13%. In the past year, price increased by 76.21%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.81 | 323.48B | ||
AMGN | AMGEN INC | 13.07 | 145.92B | ||
GILD | GILEAD SCIENCES INC | 13.81 | 133.07B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.14B | ||
REGN | REGENERON PHARMACEUTICALS | 13.43 | 64.25B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.62B | ||
ARGX | ARGENX SE - ADR | 99.06 | 35.50B | ||
ONC | BEIGENE LTD-ADR | 5.93 | 25.73B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.81B | ||
NTRA | NATERA INC | N/A | 20.92B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.12B | ||
BIIB | BIOGEN INC | 8.01 | 18.56B |
Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. The company is headquartered in Burlingame, California and currently employs 31 full-time employees. The company went IPO on 2016-03-23. The firm is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. ITK, an enzyme that functions in T cell signaling and differentiation, is expressed predominantly in T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.
CORVUS PHARMACEUTICALS INC
863 Mitten Rd Ste 102
Burlingame CALIFORNIA 94010 US
CEO: Richard A. Miller
Employees: 31
Phone: 16509004520
The current stock price of CRVS is 3.565 USD. The price decreased by -1.79% in the last trading session.
The exchange symbol of CORVUS PHARMACEUTICALS INC is CRVS and it is listed on the Nasdaq exchange.
CRVS stock is listed on the Nasdaq exchange.
12 analysts have analysed CRVS and the average price target is 15.3 USD. This implies a price increase of 329.17% is expected in the next year compared to the current price of 3.565. Check the CORVUS PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CORVUS PHARMACEUTICALS INC (CRVS) has a market capitalization of 243.03M USD. This makes CRVS a Micro Cap stock.
CORVUS PHARMACEUTICALS INC (CRVS) currently has 31 employees.
CORVUS PHARMACEUTICALS INC (CRVS) has a support level at 3.39 and a resistance level at 3.64. Check the full technical report for a detailed analysis of CRVS support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CRVS does not pay a dividend.
CORVUS PHARMACEUTICALS INC (CRVS) will report earnings on 2025-08-04.
CORVUS PHARMACEUTICALS INC (CRVS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.61).
The outstanding short interest for CORVUS PHARMACEUTICALS INC (CRVS) is 10.69% of its float. Check the ownership tab for more information on the CRVS short interest.
ChartMill assigns a technical rating of 4 / 10 to CRVS. When comparing the yearly performance of all stocks, CRVS is one of the better performing stocks in the market, outperforming 93.03% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to CRVS. CRVS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months CRVS reported a non-GAAP Earnings per Share(EPS) of -0.61. The EPS decreased by -17.31% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -90.4% | ||
ROE | -191.27% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 87% to CRVS. The Buy consensus is the average rating of analysts ratings from 12 analysts.